UBS launched its coverage of Sagimet Biosciences (NASDAQ:SGMT) with a buy recommendation and a $12 price target, calling the company an underappreciated player in the market for liver disorder, ...

Monsta Mash/ – Following Trump’s win and consequent bull market euphoria, the new crypto assets are receiving a major boost. Pepe coin continues to affirm its place as one of the top-performing tokens ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attention as potential treatments for a variety of ...

The "Monster Mash" was more than just a graveyard smash — it was also banned in the U.K. for many years! Learn about the ...

With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...

Novo Nordisk’s Wegovy helped people with a fatty liver disease called MASH experience improvements in liver scarring and achieve symptom resolution, new data show.

In its second full quarter on the market, the fatty liver disease drug racked up sales of $62 million, which routed Wall ...

Study participants were randomly assigned 2:1 to receive once-weekly subcutaneous semaglutide 2.4mg or placebo alongside standard of care. The primary endpoints for part 1 were resolution of ...

This article reveals the top 3 crypto gems with the potential for explosive growth in 2025. For those seeking the next big ...